New Delhi, Nov 9 (PTI) Drug firm Lupin on Monday said the US health regulator has issued 13 observations after inspection of its subsidiary's Somerset facility in New Jersey.

In a regulatory filing, Lupin said the inspection by US Food and Drug Administration (USFDA) commenced on September 10, 2020, and concluded on November 5, 2020. The duration of the inspection was prolonged due to COVID-related delays and challenges.

Also Read | Indian Markets Open at Record High; Sensex Rallies Over 650 Points.

The inspection has closed with 13 observations, it said.

"We are confident of addressing these observations and will work closely with the agency to address their concerns," the company said.

Also Read | Hyderabad Police to Relaunch Job Connect; The Initiative Aims to Fill Gap Between the Companies and Job Seekers.

Lupin said it does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The facility contributes less than 5 per cent of our global revenues, it added.

Shares of Lupin were trading 0.52 per cent lower at Rs 911.60 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)